Eterna Therapeutics Inc.
(ERNA)
undefined
undefined%
At close: undefined
0.33
-4.35%
Pre-market Jan 07, 2025, 06:54 AM EST
Company Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer.
Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck.
The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Eterna Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 29, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Sanjeev Luther |
Contact Details
Address: 10355 Science Center Drive San Diego, California United States | |
| Website | https://www.brooklynitx.com |
Stock Details
| Ticker Symbol | ERNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000748592 |
| CUSIP Number | 114082209 |
| ISIN Number | US1140822099 |
| Employer ID | 31-1103425 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanjeev Luther | Chief Executive Officer, President & Director |
| Dorothy J. Clarke | General Counsel & Director |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 03, 2025 | 8-K | Current Report |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 14, 2024 | D | Filing |
| Nov 14, 2024 | D | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | S-1 | Filing |
| Nov 05, 2024 | 4 | Filing |
| Oct 29, 2024 | 8-K | Current Report |